Real-World Financial and Clinical Impact of Diagnostic-Driven and Empirical-Treatment Strategies in High-Risk Immunocompromised Patients with Suspected Aspergillus Infection in the United Kingdom-Reference-Cited by-同舟云学术

Real-World Financial and Clinical Impact of Diagnostic-Driven and Empirical-Treatment Strategies in High-Risk Immunocompromised Patients with Suspected Aspergillus Infection in the United Kingdom

Published:2022-06-29 Issue:3 Volume:10 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Earnshaw Stephanie R.¹^ORCID,McDade Cheryl¹^ORCID,Bryan Andrew²,Ines Monica³,Micallef Christianne⁴,Sung Anita⁵,Enoch David A.⁴

Affiliation:

1. RTI Health Solutions, Research Triangle Park, North Carolina, USA

2. Pfizer Biopharmaceuticals Group, Pfizer Ltd., Surrey, United Kingdom

3. Hospital & Vaccines Business Unit, Pfizer, Inc., Porto-Salvo, Portugal

4. Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

5. Pfizer, Inc., New York, New York, USA

Abstract

Patients at risk of invasive fungal infections (IFIs), such as Aspergillus spp., tend to be immunocompromised and usually take several medications which may generate many side effects. Prescribing is further complicated by comorbidities, drug interactions and challenges accessing diagnostics.

Funder

Pfizer

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.00425-22

Reference60 articles.

1. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors

2. Isolation of Aspergillus species from the airway of lung transplant recipients is associated with excess mortality

3. The Changing Epidemiology of Invasive Fungal Infections

4. Estimating the burden of invasive and serious fungal disease in the United Kingdom

5. Empirical versus Preemptive Antifungal Therapy for High‐Risk, Febrile, Neutropenic Patients: A Randomized, Controlled Trial

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Machine learning to identify clinically relevant Candida yeast species;Medical Mycology;2023-12-21

2. Machine learning to identify clinically relevantCandidayeast species;2023-09-10

3. Comparing the Real-World Use of Isavuconazole to Other Anti-Fungal Therapy for Invasive Fungal Infections in Patients with and without Underlying Disparities: A Multi-Center Retrospective Study;Journal of Fungi;2023-01-27

4. Erratum for Earnshaw et al., “Real-World Financial and Clinical Impact of Diagnostic-Driven and Empirical-Treatment Strategies in High-Risk Immunocompromised Patients with Suspected Aspergillus Infection in the United Kingdom”;Microbiology Spectrum;2022-10-26